Does Medicare Cover Weight-Loss Medication? 2026 Guide

Creator: Dr. Tran Le, MD, DABOM
Published: 2026-06-23T13:36:41+00:00

If you're on Medicare and wondering whether your plan will help pay for a GLP-1 medication, the honest answer is: it depends on why it's prescribed, and 2026 is a turning point. A brand-new federal demonstration is about to put certain weight-loss drugs within reach for a $50 monthly copay. Here's exactly where things stand, written plainly so you can make a confident decision.

This is educational information, not personal medical advice. Our clinic is physician-led by Dr. Tran Le, MD, DABOM (triple board-certified in Obesity Medicine, Addiction Medicine, and Occupational & Environmental Medicine), and we help patients across Texas and Utah sort through these options every week.

Does Medicare cover weight-loss medication in 2026?

The short version: traditional Medicare Part D does not cover a GLP-1 when it's prescribed solely for weight loss, but a temporary federal program now provides a path to coverage for some people.

For decades, federal law has blocked this. Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss, among several other "excluded" categories of drugs and indications. That exclusion dates back to the law that created Part D. When Part D was created under the Medicare Modernization Act of 2003, the law barred coverage for the class of drugs aimed at weight gain or weight loss.

In 2024, CMS proposed reinterpreting that exclusion to allow coverage of anti-obesity medications, but the proposal was not finalized. In April 2025, CMS chose not to make this proposal final, thus leaving GLP-1 covered by Medicare only if the beneficiary is prescribed the drug for a diagnosis of diabetes, cardiovascular diseases, or some other eligible diagnosis. Broadly changing the law would take an act of Congress. Changing the law to permit or require Medicare Part D plans to cover medications for weight loss would require Congress to act.

When is a GLP-1 covered under Part D?

Here's the key nuance many people miss: the same molecule can be covered or excluded depending on the diagnosis. Under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).

In our practice, patients are often surprised to learn that GLP-1 drugs prescribed for type 2 diabetes, obstructive sleep apnea, or to lower cardiovascular risk may already be covered through their regular Part D plan, while the exact same therapy aimed only at the number on the scale is not. If you have one of those qualifying diagnoses, talk with your prescriber about whether your plan's formulary covers your medication for that indication.

The Medicare GLP-1 Bridge: $50/month starting July 2026

This is the big 2026 change. Starting in July 2026, some people with Medicare will be eligible for Medicare coverage of certain weight-loss medications through the new Medicare GLP-1 Bridge Program. The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.

The cost is fixed and predictable. Under the demonstration eligible Medicare beneficiaries will pay $50 for a month of GLP-1 medications. One catch worth knowing: the $50 copays won't count towards Part D deductibles or the $2,100 cap on out-of-pocket spending.

Importantly, this runs separately from your normal drug plan. The GLP-1 payment demonstration will operate outside of the Medicare Part D benefit's coverage and payment flow, which means that Part D Plan Sponsors will not carry risk for eligible GLP-1 products furnished under the demonstration. A central CMS processor handles approvals and payments rather than your plan.

Which medications are included?

The Bridge covers specific drugs that are FDA-approved for weight management. The Bridge program currently covers specific GLP-1 medications that hold FDA approval for weight loss. This includes Foundayo, Wegovy (injection and tablets), and Zepbound (KwikPen). Notably, Ozempic and Mounjaro are not included in this program.

Who qualifies?

Eligibility is built around your enrollment and clinical history. Key clinical eligibility criteria include: (i) a body mass index (BMI) of 35 or greater; (ii) a BMI of 30 or greater with a diagnosis of either heart failure, uncontrolled hypertension, or chronic kidney disease; or (iii) a BMI of 27 or greater with a diagnosis of either pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease. You also have to be enrolled in the right plan type: a Medicare Part D prescription drug plan, including Medicare Advantage plans that include drug coverage.

If you've already started a GLP-1 and have since lost weight, there's good news on how the criteria are applied. Clinical criteria are assessed at the time GLP-1 therapy was first initiated, including for beneficiaries who started therapy before enrolling in Medicare Part D or before the July 1, 2026 launch of the Bridge.

There's an important exception: if your diagnosis already qualifies for normal Part D coverage, you use that instead. Type 2 diabetes, obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage. Beneficiaries with these diagnoses are eligible to receive GLP-1s through their Part D plan and therefore are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria.

How the process works

Your doctor drives the paperwork. Instead of going through your regular Part D plan, you will need prior authorization. Your doctor will send the prescription to a central system run by a CMS contractor, using a system already in place for another Medicare drug program. Once they get approval, patients will pay the flat $50 copayment at the pharmacy when they pick up the prescription.

Which brands does Medicare cover: Wegovy, Zepbound, Ozempic, Mounjaro?

Short version: the weight-loss brands (Wegovy and Zepbound) are covered through the Bridge for the $50 copay, while the diabetes brands (Ozempic and Mounjaro) are covered by regular Part D only for diabetes, not weight loss. For the full drug-by-drug breakdown, including the Wegovy pill, Foundayo, and which Medicare plans (Aetna, Humana, UnitedHealthcare) apply, see our dedicated guide: Does Medicare cover Zepbound, Wegovy, Ozempic, or Mounjaro?

How these medications actually work

Understanding the mechanism helps explain why diagnosis matters so much for coverage. GLP-1 receptor agonists mimic a natural gut hormone. Centrally, GLP-1 RAs modulate brain regions controlling appetite, influencing neurotransmitter and peptide release to regulate hunger and energy expenditure. Peripherally, GLP-1 RAs improve glycemic control by enhancing insulin secretion, reducing glucagon release, delaying gastric emptying, and regulating gut hormones. In plain terms, they help you feel full sooner, stay full longer, and steady your blood sugar, which is why the same drug class treats diabetes, cardiovascular risk, and obesity.

What about beyond 2027?

The Bridge is intentionally temporary. It's meant to "bridge" the gap before a longer-term program that might (or might not) begin in 2028. A broader effort called the BALANCE Model has been proposed but its Medicare Part D rollout has been delayed, so for now the Bridge is the concrete option. If long-term, predictable access matters to you, it's worth planning ahead with your clinician rather than assuming coverage will simply continue.

Frequently asked questions

Does Medicare cover Wegovy or Zepbound for weight loss?

Not through standard Part D when prescribed only for weight loss. However, beginning July 1, 2026, eligible beneficiaries can access certain weight-loss GLP-1s, including Wegovy and the Zepbound KwikPen, for a $50 monthly copay through the temporary Medicare GLP-1 Bridge if they meet the clinical criteria.

Will Medicare cover my GLP-1 if I have diabetes?

Potentially yes. GLP-1s prescribed for a medically accepted indication like type 2 diabetes or cardiovascular risk reduction may be covered under your regular Part D plan, subject to your plan's formulary and rules like prior authorization. Coverage always depends on your specific plan.

Are compounded GLP-1 medications covered by Medicare?

No. Compounded medications are not covered under the Bridge, which is limited to specific FDA-approved products, and compounded drugs are not FDA-approved. They remain a self-pay option for many patients who don't qualify for Bridge coverage.

Your options with TOM Weight Loss

Medicare's rules are nuanced, and not everyone will qualify for the Bridge. That's where a physician-led program helps. At our clinic, led by Dr. Le, we offer all-inclusive memberships with compounded semaglutide or tirzepatide and the medication included, plus an à la carte plan for brand-name GLP-1s. (Compounded medications are not FDA-approved and are not the same as brand-name drugs.) If you'd like to understand how the GLP-1 Bridge applies to you, our Medicare GLP-1 bridge guide and how it works pages walk through next steps.

Ready to talk it through with a real clinic? Start your consultation and we'll help you find the most sensible, affordable path, whether that's Medicare coverage, brand-name, or a membership plan.